Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter.

p53 transactivates the expression of a variety of genes by binding to specific DNA sequences within the promoter. We have investigated the ability of wild-type p53 and a non-DNA binding p53 mutant to activate the hepatocyte growth factor/scatter factor (HGF/SF) promoter using chloramphenicol acetyltransferase reporter constructs. We also used deletion sequences of the HGF/SF promoter to identify which regions, if any, were responsible for p53 binding. Our results show that wild-type but not mutant p53 activates the HGF/SF promoter when using -3000 and -755 bp upstream of the HGF/SF gene. This activation is lost when promoter sequences covering -365 and -239 bp are used. Analysis of the DNA sequence between -365 and -755 bp shows one putative p53 half-site with 80% homology to the consensus sequence and another half-site 3 bases downstream of this with 100% homology to the consensus sequence. In contrast to previously identified p53 binding DNA sequences, the downstream half-site is inverted. We propose that the HGF/SF promoter can be activated by wild-type p53 in vivo and that this could be as a result of a novel form of sequence-specific DNA binding.

[1]  R. Ball,et al.  Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. , 1996, British Journal of Cancer.

[2]  Hisashi Tanaka,et al.  Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: Increased frequency and different spectrum of mutations from primary tumors , 1996, International journal of cancer.

[3]  N. Tatsumi,et al.  Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells. , 1996, British Journal of Cancer.

[4]  M. Rugge,et al.  p53 Overexpression in the Multistep Process of Esophageal Carcinogenesis , 1995, The American journal of surgical pathology.

[5]  H. Osugi,et al.  Expression of immunoreactive human hepatocyte growth factor in human esophageal squamous cell carcinomas. , 1995, Cancer letters.

[6]  K. Cooper.  p53 mutations in human papillomavirus-associated oesophageal squamous cell carcinoma. , 1995, British Journal of Cancer.

[7]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[8]  S. Nakamura,et al.  Hepatocyte growth factor--pleiotropic cytokine produced by human leukemia cells. , 1995, Leukemia & lymphoma.

[9]  T. Shin,et al.  p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53 , 1995, Molecular and cellular biology.

[10]  J. Milner,et al.  Specific DNA binding by different classes of human p53 mutants. , 1995, Oncogene.

[11]  L. Donehower,et al.  Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. , 1995, Cancer research.

[12]  M. Sharpe,et al.  Scatter factor/hepatocyte growth factor is essential for liver development , 1995, Nature.

[13]  W. Birchmeier,et al.  Characterization of the Scatter Factor/Hepatocyte Growth Factor Gene Promoter , 1995, The Journal of Biological Chemistry.

[14]  G. V. Vande Woude,et al.  The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. , 1995, EXS.

[15]  I. Yamamoto,et al.  Induction of hepatocyte growth factor in human skin fibroblasts by epidermal growth factor, platelet-derived growth factor and fibroblast growth factor. , 1994, Cytokine.

[16]  Y. Matsuo,et al.  Significant amount of hepatocyte growth factor detected in blood and bone marrow plasma of leukaemia patients , 1994, British journal of haematology.

[17]  M. Oren.  Relationship of p53 to the control of apoptotic cell death. , 1994, Seminars in cancer biology.

[18]  S. Deb,et al.  Wild-type human p53 activates the human epidermal growth factor receptor promoter. , 1994, Oncogene.

[19]  F. Vikhanskaya,et al.  Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. , 1994, Nucleic acids research.

[20]  T. Nakamura,et al.  Partial purification and characterization of 'injurin-like' factor which stimulates production of hepatocyte growth factor. , 1994, Biochimica et biophysica acta.

[21]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[22]  K. Watabe,et al.  Characterization of the 5'-flanking region of the hepatocyte growth factor gene. , 1993, Biochemical and biophysical research communications.

[23]  K. Matsumoto,et al.  Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. , 1992, The Journal of biological chemistry.

[24]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[25]  K. Matsumoto,et al.  Up-regulation of hepatocyte growth factor gene expression by interleukin-1 in human skin fibroblasts. , 1992, Biochemical and biophysical research communications.

[26]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[27]  K. Matsumoto,et al.  Identification and characterization of "injurin," an inducer of expression of the gene for hepatocyte growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[29]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[30]  K. Matsumoto,et al.  Hepatocyte growth factor: molecular structure, roles in liver regeneration, and other biological functions. , 1992, Critical reviews in oncogenesis.

[31]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[32]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[33]  J. Rubin,et al.  A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Nakamura,et al.  Expression of hepatocyte growth factor gene in endothelial and Kupffer cells of damaged rat livers, as revealed by in situ hybridization. , 1990, Biochemical and biophysical research communications.

[35]  J Vandekerckhove,et al.  Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells , 1990, The Journal of cell biology.

[36]  M. Nagao,et al.  Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor. , 1990, Biochemical and biophysical research communications.

[37]  B. Howard,et al.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells , 1982, Molecular and cellular biology.

[38]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.

[39]  P. C. Sylvester-Bradley.  Natural Causes of Life , 1972, Nature.